STAT+: Pharmalittle: We’re reading about a Lilly access program, a Gilead court victory, and more
Eli Lilly confirmed that it will allow more patients to apply for early access to retatrutide, an unapproved obesity drug
A 79-year-old patient received special access to an unapproved obesity drug, retatrutide, following a request from Eli Lilly, STAT reports. The company has now announced it will allow other patients to apply for early access. This marks a notable shift in the company's public stance, which previously provided limited information about the special access program.
The move follows a California Supreme Court victory for Gilead Sciences in a case brought by thousands of patients who accused the company of negligence for delaying the development of an HIV medication that was safer than another drug they were already selling. The court ruled in favor of Gilead, overturning a previous decision that held the company liable.
This landmark decision has sparked concerns within the pharmaceutical industry about how legal liability might affect drug development and innovation.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
